{ "ground": "Five instituted grounds: (1) anticipation by Morales-Sanfrutos as evidenced by Straus; (2) anticipation/obviousness over Harris; (3) obviousness over Singh in view of Harris; (4) obviousness over Singh, Harris, and Bhakta; and (5) obviousness over Singh, Harris, and Snow.", "overall_outcome": "mixed", "claim_outcomes": [ {"claim_id": "1", "outcome": "unpatentable"}, {"claim_id": "2", "outcome": "unpatentable"}, {"claim_id": "3", "outcome": "unpatentable"}, {"claim_id": "4", "outcome": "unpatentable"}, {"claim_id": "5", "outcome": "unpatentable"}, {"claim_id": "6", "outcome": "unpatentable"}, {"claim_id": "7", "outcome": "unpatentable"}, {"claim_id": "8", "outcome": "unpatentable"}, {"claim_id": "9", "outcome": "unpatentable"}, {"claim_id": "10", "outcome": "unpatentable"}, {"claim_id": "11", "outcome": "unpatentable"}, {"claim_id": "12", "outcome": "unpatentable"}, {"claim_id": "13", "outcome": "unpatentable"}, {"claim_id": "14", "outcome": "unpatentable"}, {"claim_id": "15", "outcome": "unpatentable"}, {"claim_id": "16", "outcome": "unpatentable"}, {"claim_id": "17", "outcome": "unpatentable"}, {"claim_id": "20", "outcome": "unpatentable"}, {"claim_id": "21", "outcome": "unpatentable"}, {"claim_id": "24", "outcome": "unpatentable"}, {"claim_id": "25", "outcome": "not_shown"}, {"claim_id": "26", "outcome": "not_shown"}, {"claim_id": "29", "outcome": "unpatentable"}, {"claim_id": "30", "outcome": "unpatentable"}, {"claim_id": "31", "outcome": "unpatentable"}, {"claim_id": "32", "outcome": "not_shown"}, {"claim_id": "33", "outcome": "not_shown"}, {"claim_id": "34", "outcome": "not_shown"} ], "claim_construction": [ { "term": "Y", "construction": "Y is the claim-recited functional group that enables reaction with a cell-binding agent, but it need not independently provide all reactivity without an adjacent Q or T. For a terminal vinyl sulfone, the vinyl portion may be mapped to Y or Z and the sulfone portion may be mapped to Q or T, subject to the claim's m/n and Markush provisos.", "why": "The claim language does not say independently. The specification and prosecution/reexamination history treat vinyl-sulfone-containing linkers as within the claimed formula when the required additional Q/T structure is present. The Lees amendment is best read as requiring the additional Q/T group when sulfone is used, not as excluding the vinyl/sulfone split mapping." }, { "term": "cell-binding agent", "construction": "For Formula II conjugates, Cb must be an actual cell-binding agent: a molecule or agent that binds to, complexes with, or reacts with a moiety of a cell population sought to be therapeutically or otherwise biologically modified. For Formula I and IV precursor claims, no actual Cb is required; the claim requires a Y group capable of reacting with such an agent.", "why": "The specification supplies the contextual definition, and the claim families are different. Formula I and IV recite only a reactive Y precursor; Formula II recites Cb itself. This distinction is dispositive for Morales-Sanfrutos/Straus because HRP is used as a reporter/labeling protein, while Singh's antibodies are cell-binding agents in the ADC sense." }, { "term": "claim 26 phosphinate requirement", "construction": "Claim 26 is a separate Formula II conjugate claim requiring the conjugate to comprise at least one -P(=O)(OM)- group.", "why": "The instituted Singh/Harris theory uses sulfone/vinyl-sulfone substitutions. Proving claim 24's two-sulfone Formula II conjugate does not prove claim 26's phosphinate limitation." } ], "rationale_to_combine": "Harris and Singh are close linker/conjugation references. Singh teaches PEG ADC linkers, antibodies as cell-binding agents, maytansinoid drugs, and reactive groups including maleimide, haloacetamide, NHS ester, and vinyl sulfone for amine/thiol reactions. Harris supplies the reason to use active sulfone/vinyl-sulfone PEG chemistry: water solubility, hydrolytic stability, thiol selectivity, and stable linkages to proteins and pharmaceuticals. That combination carries the main Singh/Harris claim set. Bhakta supplies a conventional val-cit/PAB protease-cleavable ADC linker component for claims 9 and 13. Snow does not carry its dependent-claim ground because the Petition does not adequately explain why a POSA would select the particular Snow bis-vinyl-sulfone genus members and replace more than Singh's terminal maleimide-containing group.", "key_disputes": [ { "argument": "Patent Owner argues Y must independently enable reaction with a cell-binding agent, so the vinyl of a vinyl sulfone cannot be Y while sulfone is Q or T.", "resolution": "Rejected. The better construction permits the split vinyl/sulfone mapping, subject to each claim's express provisos. That defeats the broad Y-based attacks on Morales-Sanfrutos, Harris, and Singh/Harris." }, { "argument": "Patent Owner argues Morales-Sanfrutos and Straus do not disclose a cell-binding agent.", "resolution": "Partly succeeds. Claim 1 and claim 2 do not require an actual Cb, so the argument does not defeat those linker claims. It does defeat Morales-Sanfrutos anticipation of Formula II claims 3, 6, 24, 25, and 33 because HRP is not shown to be a Cb in the claimed conjugate context." }, { "argument": "Patent Owner argues Singh/Harris merely substitutes terminal reactive groups and never supplies Q/T spacer elements.", "resolution": "Mostly rejected under the adopted Y construction. Substituting vinyl sulfone for Singh's thiol-reactive groups supplies vinyl as Y or Z and sulfone as Q or T; Harris provides the motivation and expectation of success. But this theory supplies sulfone, not the phosphinate required by claim 26." }, { "argument": "Patent Owner argues the Ground 5 Snow theory is hindsight and underexplained.", "resolution": "Succeeds for claims 25 and 32-34, and Ground 5 does not prove claim 2. The Petition relies on a broad Snow formula and a conclusory replacement of Singh's maleimide-containing arm without explaining the selected Snow variables or the replacement of adjacent linker structure." }, { "argument": "Patent Owner argues claim 2 fails with the Snow theory.", "resolution": "Even if Ground 5 fails for claim 2, claim 2 is still unpatentable because Morales-Sanfrutos compound 2 anticipates claim 2 when its amino-containing propargylamine group is mapped to Z and the vinyl-sulfone end supplies the Y/Q side." } ], "ground_analysis": [ { "ground_id": "1", "basis": "Morales-Sanfrutos as evidenced by Straus", "disposition": "succeeds for claims 1 and 2; not shown for claims 3, 6, 24, 25, and 33", "analysis": "Morales-Sanfrutos discloses bifunctional vinyl-sulfone/PEG tag reagents that meet Formula I under the adopted Y construction. Claim 2 is met by compound 2's amino-containing propargylamine Z group. But the HRP-11 Formula II theory requires Cb, and the visible record shows HRP used as a reporter enzyme/labeling substrate, not as a cell-binding agent of the claimed conjugate." }, { "ground_id": "2", "basis": "Harris", "disposition": "succeeds for claims 1, 20, 21, and 29-31", "analysis": "Harris' active sulfone PEG derivatives, including PEG bis-vinyl sulfone and heterobifunctional sulfone/NHS ester derivatives, disclose or render obvious the Formula I and Formula IV linker/drug-linker claims. The at-once-envisage objection is weak because Harris expressly identifies vinyl sulfone/haloethyl sulfone end groups, PEG bis-vinyl sulfone, pharmaceuticals modified with thiols, and NHS-type chemistry." }, { "ground_id": "3", "basis": "Singh in view of Harris", "disposition": "succeeds for claims 1-8, 10-12, 14-17, 20, 21, 24, and 29-31; not shown for claim 26", "analysis": "Singh supplies PEG ADC linker scaffolds, drugs, antibodies, cell-binding agents, drug loading, cytotoxicity, and reactive functionalities. Singh itself identifies vinyl sulfone as a thiol-reactive alternative to maleimide/haloacetamide, and Harris supplies active sulfone advantages. The combination therefore supports the sulfone-based Formula I, II, and IV claims, but it does not supply claim 26's at-least-one-phosphinate requirement." }, { "ground_id": "4", "basis": "Singh in view of Harris and Bhakta", "disposition": "succeeds for claims 9 and 13", "analysis": "Once claim 3 is shown by Singh/Harris, Bhakta's val-cit/PAB protease-cleavable ADC linker teaching supplies claim 9's linker component and claim 13's protease-cleavable feature. The Petition's identification of replacing Singh's disulfide release linkage is sufficient in view of the known interchangeability of ADC cleavable release linkers." }, { "ground_id": "5", "basis": "Singh in view of Harris and Snow", "disposition": "not shown for claims 25 and 32-34; not needed and not persuasive for claim 2", "analysis": "The Snow theory is not adequately articulated. Snow discloses broad polyalkylene oxide vinyl-sulfone genera, but the Petition does not explain the specific variable selections or why a POSA would replace not just the maleimide terminus but adjacent linker/amide structure in Singh. Claim 2 remains unpatentable through Ground 1." } ], "claim_reasoning": [ { "claim_id": "1", "outcome": "unpatentable", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 31", "quote": "Claim 1 does not require actual conjugation to a cell-binding agent." }, { "document": "Morales-Sanfrutos (EX1005)", "pinpoint": "p. 4041", "quote": "vinyl sulfone is an appealing function for protein conjugation through the Michael-type addition" }, { "document": "Harris (EX1007)", "pinpoint": "19:10-15", "quote": "the active sulfone moieties comprise vinyl sulfone" } ], "analysis": "Claim 1 is a Formula I linker claim, not a conjugate requiring an actual Cb. Under the adopted Y construction, Morales-Sanfrutos' bifunctional vinyl-sulfone PEG reagents disclose the required Y/Q and T/Z architecture, and Harris independently discloses or renders obvious PEG bis-vinyl-sulfone linkers. Claim 1 is unpatentable under Grounds 1, 2, and 3." }, { "claim_id": "2", "outcome": "unpatentable", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 32", "quote": "Morales-Sanfrutos' compound 2 has an amino group." }, { "document": "Morales-Sanfrutos (EX1005)", "pinpoint": "p. 4041", "quote": "compound 2 bearing three orthogonal functional groups (i.e., amine, vinyl sulfone, and terminal alkyne)" } ], "analysis": "Claim 2 depends from claim 1 and requires Z to comprise, among other options, an amino group. Morales-Sanfrutos compound 2 supplies an amino-containing propargylamine Z group while the other end supplies the vinyl-sulfone Y/Q mapping. Ground 5's Snow theory is not persuasive for claim 2, but claim 2 is still unpatentable under Ground 1." }, { "claim_id": "3", "outcome": "unpatentable", "record_support": [ { "document": "Singh (EX1008)", "pinpoint": "para. 15", "quote": "Another aspect of the present invention is a cell binding agent drug conjugate of formula (2)" }, { "document": "Singh (EX1008)", "pinpoint": "para. 134", "quote": "for thiol-reactive functionality, the functionality could be a maleimide, a halo acetamide, or a vinyl sulfone" }, { "document": "Harris (EX1007)", "pinpoint": "19:34-37", "quote": "can enable otherwise insoluble molecules to pass into solution when conjugated with the derivative" } ], "analysis": "Morales-Sanfrutos does not prove claim 3 because its HRP-11 theory lacks a shown Cb. Singh/Harris does prove claim 3: Singh discloses ADCs with CB, drug, PEG linkers, and reactive groups; Singh expressly identifies vinyl sulfone as a thiol-reactive alternative; and Harris supplies the reason to use active sulfone PEG chemistry. Claim 3 is unpatentable under Ground 3." }, { "claim_id": "9", "outcome": "unpatentable", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 71", "quote": "valine-citrulline was a well-known cleavable dipeptide used to link drugs in ADCs" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 72", "quote": "motivated to use the well-known val-cit-PAB linker of Bhakta to replace, e.g., the disulfide linkage of Singh" }, { "document": "Bhakta (EX1011)", "pinpoint": "para. 267", "quote": "Val is valine; Cit is citrulline; p is 1, 2, 3, or 4" } ], "analysis": "Claim 9 depends from claim 3 and adds listed linker components including valine-citrulline and p-aminobenzyloxycarbonyl-type components. With the Singh/Harris base conjugate established, Bhakta supplies the conventional val-cit/PAB ADC linker component. Claim 9 is unpatentable under Ground 4." }, { "claim_id": "13", "outcome": "unpatentable", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 71", "quote": "optimized in their selectivity for enzymatic cleavage by...for example, a tumor-associated protease" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 72", "quote": "when the val-cit dipeptide is cleaved from the PAB by cathepsins associated with the target cancer cell" } ], "analysis": "Claim 13 requires the conjugate to be cleavable by a protease. Bhakta expressly supplies protease-cleavable val-cit/PAB ADC linker chemistry, and a POSA would have been motivated to replace Singh's disulfide release linkage to obtain more selective target-cell drug release. Claim 13 is unpatentable under Ground 4." }, { "claim_id": "20", "outcome": "unpatentable", "record_support": [ { "document": "Harris (EX1007)", "pinpoint": "6:28-31", "quote": "Pharmaceuticals from aspirin to penicillin can be usefully modified" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 42", "quote": "Harris' also discloses heterobifunctional PEG derivatives comprising a single sulfone moiety" }, { "document": "Singh (EX1008)", "pinpoint": "para. 14", "quote": "Z represents a reactive functionality that can form an amide or a thioether bond" } ], "analysis": "Claim 20 is a Formula IV drug-linker precursor claim. Harris discloses or renders obvious sulfone/NHS heterobifunctional PEG derivatives linked to pharmaceuticals, and Singh/Harris independently suggests the same drug-linker architecture. The single-sulfone Markush proviso is satisfied by NHS-type Y in the Harris/Singh mappings. Claim 20 is unpatentable under Grounds 2 and 3." }, { "claim_id": "24", "outcome": "unpatentable", "record_support": [ { "document": "Singh (EX1008)", "pinpoint": "para. 84", "quote": "CB represents a cell-binding agent; D represents a drug" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 64", "quote": "a POSA would have been motivated to prepare ADCs with one or two sulfones using vinyl sulfones" }, { "document": "Harris (EX1007)", "pinpoint": "6:12-15", "quote": "highly selective for coupling with thiol moieties instead of amino moieties" } ], "analysis": "Morales-Sanfrutos does not prove claim 24 because HRP is not shown to be Cb. Singh/Harris does prove claim 24, which requires Formula II with m and n from 1 to 5. Singh supplies actual antibody/drug conjugates and Harris/Singh provide the motivation to use vinyl-sulfone substitutions to supply both sulfone Q and T. Claim 24 is unpatentable under Ground 3." }, { "claim_id": "25", "outcome": "not_shown", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 74", "quote": "replace at least one of the maleimide-containing arms in Singh's bifunctional bis-maleimide PEG crosslinking agent" }, { "document": "Snow (EX1010)", "pinpoint": "7:51-65", "quote": "PAO is a polyalkylene oxide having an average molecular weight in the range of 250 to 200,000 daltons" } ], "analysis": "Claim 25 depends from claim 24 and is reached only by Morales-Sanfrutos/Straus and Snow-based Ground 5. Morales-Sanfrutos fails because HRP is not shown to be Cb. Ground 5 fails because the Petition does not sufficiently explain why a POSA would select the specific Snow bis-vinyl-sulfone structure and substitute the required segment into Singh to make every remaining R group alkyl or PEG. Claim 25 is not shown unpatentable." }, { "claim_id": "26", "outcome": "not_shown", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 64", "quote": "a POSA would have been motivated to prepare ADCs with one or two sulfones using vinyl sulfones" }, { "document": "Singh (EX1008)", "pinpoint": "para. 134", "quote": "for thiol-reactive functionality, the functionality could be a maleimide, a halo acetamide, or a vinyl sulfone" }, { "document": "Harris (EX1007)", "pinpoint": "6:8-11", "quote": "having one or more active sulfone moieties" } ], "analysis": "Claim 26 is an independent Formula II claim requiring at least one phosphinate group. The Petition's Ground 3 theory for claim 26 is the same Singh/Harris vinyl-sulfone/sulfonyl substitution theory used for claim 24. That supplies sulfone, not phosphinate, and the Petition does not identify a Singh/Harris teaching or motivation that supplies the required -P(=O)(OM)- group. Claim 26 is not shown unpatentable." }, { "claim_id": "29", "outcome": "unpatentable", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 54", "quote": "Singh discloses formula (1), Z-X1-(-CH2-CH2-O-)n-Yp-D" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 55", "quote": "Y of formula (IV) is vinyl, Q is sulfonyl, m=1" }, { "document": "Singh (EX1008)", "pinpoint": "para. 80", "quote": "n is an integer from 1 to 2000" } ], "analysis": "Claim 29 is a Formula IV drug-linker claim with the additional R2 and Y provisos. Harris and Singh/Harris both teach or suggest the required drug-linker structure. For the one-sulfone situation, the Petition maps NHS-type Y to the Markush list; for two-sulfone embodiments, the vinyl-sulfone substitution supplies the sulfone/vinyl groups and Singh's PEG supplies the R limitations. Claim 29 is unpatentable under Grounds 2 and 3." }, { "claim_id": "30", "outcome": "unpatentable", "record_support": [ { "document": "Harris (EX1007)", "pinpoint": "16:34-17:5", "quote": "can be used to link more than one biologically active molecule to the PEG" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 56", "quote": "Singh's Y group in formula (I) can also provide a first or second sulfonyl group" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 60", "quote": "motivated to substitute thiol reactive groups...with vinyl sulfone or other sulfones as taught by Harris" } ], "analysis": "Claim 30 requires Formula IV with m and n from 1 to 5, so both Q and T must be present. Harris' PEG bis-vinyl-sulfone disclosure and the Singh/Harris two-end vinyl-sulfone substitution both supply two sulfone groups under the adopted construction, with the PEG spacer satisfying the R/PEG requirements. Claim 30 is unpatentable under Grounds 2 and 3." }, { "claim_id": "32", "outcome": "not_shown", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 74", "quote": "replace at least one of the maleimide-containing arms...with the bis-vinyl sulfone group of Snow" }, { "document": "Snow (EX1010)", "pinpoint": "claims 1-10", "quote": "R4 is H or an alkyl or an aralkyl group of 1 to 8 carbon atoms" } ], "analysis": "Claim 32 depends from claim 31 and is reached only by Ground 5. The Petition's Snow theory is too conclusory to show the required all-remaining-R alkyl/PEG limitation because it does not justify the particular Snow genus selections or the larger structural replacement in Singh. Claim 32 is not shown unpatentable." }, { "claim_id": "33", "outcome": "not_shown", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 34", "quote": "Cb is horseradish peroxidase (HRP)" }, { "document": "Morales-Sanfrutos (EX1005)", "pinpoint": "p. 4043", "quote": "dual reporter groups ready to be linked to a recognition system" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 75", "quote": "The diagrams below show how the modified linkers match up with claimed linkers." } ], "analysis": "Claim 33 depends from claim 3 but is not included in Ground 3. Ground 1 fails because Morales-Sanfrutos/Straus do not show HRP as the claimed Cb. Ground 5 fails for the same Snow-selection and structural-substitution reasons that defeat claims 25 and 32. Claim 33 is not shown unpatentable." }, { "claim_id": "34", "outcome": "not_shown", "record_support": [ { "document": "Petition (Paper 2)", "pinpoint": "p. 73", "quote": "Singh and Harris are relied on to teach the various elements of claims 1, 3, 20, 24 and 30-31" }, { "document": "Petition (Paper 2)", "pinpoint": "p. 74", "quote": "replace at least one of the maleimide-containing arms...with the bis-vinyl sulfone group of Snow" }, { "document": "Snow (EX1010)", "pinpoint": "7:51-65", "quote": "A is an arylene or an aralkylene group...or an alkylene radical" } ], "analysis": "Claim 34 depends from claim 20 and is reached only by Ground 5. Although claim 20 is unpatentable under Harris and Singh/Harris, the additional claim 34 R-group requirement is not proven by the underexplained Snow substitution. Claim 34 is not shown unpatentable." } ] }